Instituto Grifols, S.A. – FDA 483
Instituto Grifols, S.A., a biologic plasma fractionation and finished drug manufacturer in Parets del Valles, Spain, was cited for two significant observations. The firm's Quality Unit lacked authority to properly investigate recurring power loss issues affecting critical systems and products, failing to link deviations or implement corrective actions. Additionally, investigations into a serious adverse event, including a patient death associated with an immunoglobulin product, were not promptly initiated or completed.
- Company
- Instituto Grifols, S.A.
- Product type
- biologics
ID · 4939d8ab-7d38-4600-a6f3-933122f8dc31
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.